Picard Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with SynCardia Total Artificial Heart Support

Core Insights - A 29-year-old patient successfully received a donor heart transplant after being supported for over 1,600 days by the SynCardia Total Artificial Heart, demonstrating the device's effectiveness as a bridge to transplant [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which produces the SynCardia Total Artificial Heart, the first total artificial heart approved by both the U.S. FDA and Health Canada [5]. - The SynCardia Total Artificial Heart is the only commercially available artificial heart in the U.S. and Canada, with over 2,100 implants performed across 27 countries [5]. Product Functionality - The SynCardia Total Artificial Heart replaces the pumping function of both sides of the heart, maintaining circulation for patients with irreversible biventricular heart failure while they await a donor organ [2][3]. - The device restores circulation and hemodynamic stability by replacing both ventricles and all four native heart valves [3]. Clinical Impact - More than 2,100 implants of the SynCardia Total Artificial Heart have been performed worldwide, with the longest documented support exceeding eight years [4]. - Extended duration support cases continue to inform clinical practice and illustrate the potential for long-term mechanical circulatory support in carefully selected patients [4].